Released Mar 20, 2023, after the close
10-K filed Mar 20, 2023, 79 days after period end · 0001140361-23-012418
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$4.49M-$4.49M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$4,737,000N/M
Operating Cash Flowderived-$5,435,000N/M
Free Cash Flowderived-$5,456,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | $1.18M | $5.17M |
| Net Income | -$4.49M | -$7.95M | -$2.22M | -$1.29M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR